

The Teva Support Solutions® Patient Support Program enrolment form¹

To enroll your patients in the Teva Support Solutions® Patient Support Program, please fax this form to **1-833-981-2254** or email it to tss.info@truximacanada.com

PATIENT INFORMATION

Last name _____ First name _____ Birthday (DD/MM/YY) _____

Sex F M Home address _____ City _____

Province _____ Postal code _____ Phone #1 _____ Phone #2 _____

Email _____ Patient has private insurance Yes No Don't know

Insurance company _____

PRESCRIPTION

Please consult the ^PrTRUXIMA® Product Monograph for important information relating to dosing, administration, adverse reactions, and drug interactions.

ORDER FOR TRUXIMA®

First treatment Subsequent treatment

Anticipated infusion date _____

First treatment
Day 1 255 minute infusion (4.25 hrs) x 1000 mg

Subsequent treatments
Day 1 255 minute infusion (4.25 hrs) x 1000 mg OR
 Alternative 120 minute infusion (2 hrs) x 1000 mg*

Day 15 195 minute infusion (3.25 hrs) x 1000 mg OR
 Alternative 120 minute infusion (2 hrs) x 1000 mg*

* Alternative 120 minute infusion is not an option for all patients. Consult Product Monograph for information on alternative administration eligibility.

Other dosing _____

PRE-MEDICATIONS

Acetaminophen

Diphenhydramine

Methylprednisolone 100 mg IV 30 min prior to infusion

Other _____

PRN MEDICATIONS FOR HYPERSENSITIVITY REACTIONS

In the event of a hypersensitivity reaction, any/all of the following medications/treatments may be given to the patient unless otherwise indicated below:

Epinephrine Other _____

Antihistamines PRN medications not required

Glucocorticoids Please specify _____

TREATMENT LEGEND

255 minute infusion (4.25 hrs): TRUXIMA® 1000 mg IV at a rate of 50 mg/hr for the first 30 minutes, increasing 50 mg/hr every 30 minutes as tolerated, for a maximum rate of 400 mg/hr.

195 minute infusion (3.25 hrs): TRUXIMA® 1000 mg IV can be started at a rate of 100 mg/hr for the first 30 minutes, increasing 100 mg/hr every 30 minutes as tolerated, for a maximum rate of 400 mg/hr.

120 minute infusion (2 hrs): TRUXIMA® 1000 mg IV can be started at a rate of 250 mg/hr for the first 30 minutes (125 mg) and then 600 mg/hr for the next 90 minutes (875 mg). Not an option for all patients. Consult Product Monograph for information on alternative administration eligibility.

Dilute TRUXIMA® in 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP.

Other instructions _____

Blood pressure meds on hold Yes No

Please specify _____

PATIENT CONSENT

I have read, understand and agree to the collection, use and disclosure of my personal information by the Teva Support Solutions[®] Patient Support Program in accordance with its privacy policy, which I have had an opportunity to review and which is attached hereto. I expressly consent to the secure storage of my personal information outside Canada, including within the European Union, Israel, or the USA, in accordance with the attached privacy policy.

Verbal consent

Written consent

Date (DD/MM/YY) _____

Date (DD/MM/YY) _____

Initials from HCP/RA nurse _____

Patient signature _____

PHYSICIAN INFORMATION AND AUTHORIZATION

I authorize the Teva Support Solutions[®] Patient Support Program to be my designated agent to forward the prescription indicated above by fax or other mode of delivery to the pharmacy chosen by the above named patient. This original prescription constitutes a legal prescription for the patient for TRUXIMA[®]. The pharmacy chosen by the patient is the only pharmacy to receive this prescription for dispensing. The original prescription will not be re-used.

Last name _____ First name _____

Specialty _____ License number _____

Work phone _____ Fax _____

Signature _____ Date (DD/MM/YY) _____

Clinic stamp

TRUXIMA[®] in combination with methotrexate is indicated to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more tumour necrosis factor inhibitor therapies.¹

For more information: Please consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00052298.PDF for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

Reference: 1. TRUXIMA[®] Product Monograph. Teva Canada Limited. July 22, 2019.

Teva Support Solutions[®] Patient Support Program privacy policy

The Teva Support Solutions[®] Patient Support Program respects your privacy and is strongly committed to protecting your personal information. This privacy policy explains the information we may collect and how we use and safeguard that information. If you have any questions, or if you wish more explanation about the manner in which we or our authorized service providers treat your personal information, or to access your personal information in our records, do not hesitate to contact us at the information provided below.

Why we ask you for personal information

In order for the Teva Support Solutions[®] Patient Support Program to offer you the services you require, we may request that you provide certain personal information to us, or we may obtain certain personal information from your referring physician, pharmacist, insurance company, public payer or any other healthcare provider or payer that may possess the requisite information. We will not collect or use any of your personal information unless you have provided your consent. We will only ask for personal information necessary to serve you and to research, develop and improve our services. Some of the services provided by the Teva Support Solutions[®] Patient Support Program include:

- providing you with personalized services to meet your specific needs;
- determining the suitability of our services to your needs;
- determining your eligibility for our products and services;
- determining eligibility for reimbursement assistance;
- providing you with information about RA, and about our products and services.

What is personal information?

Personal information is any information that could personally identify you. It includes, but is not limited to, your name, mailing address, email address, phone number, gender, or age. If you request reimbursement assistance, we may ask you to provide your financial statements, income tax records, employment records and your social insurance number.

When we ask for your personal information, we will make sure we obtain your consent, which is an informed permission you give us to store your information in our databases and to use it for the purposes we will inform you about.

Access and use of information

The personal information you provide us will be accessed only by the Teva Support Solutions[®] Patient Support Program, our affiliates and authorized agents and each of our respective staff. By agreeing to provide your information in accordance with the terms of this privacy policy, you are giving your consent for us to share relevant information from your file with your referring physician, as well as our affiliates and authorized third parties who assist us in providing services to you (i.e. only the information required for the execution of the service being required from the third party). These third parties include:

- our healthcare providers for providing appointment reminders, coordinating appointments, offering advice or follow-up about your therapy;
- our service providers for therapy coverage;
- our mailing house (responsible for sending printed information and publications); or
- potential payers or reimbursement organizations.

We might also share information with external firms which would be engaged by us to conduct pharmaceutical market research on our behalf, and who may contact you for the sole purpose of gathering market research information.

Furthermore, your information might also be shared with others if explicitly authorized or required by applicable law.

Any data which we might have shared with such third parties will be held on a confidential basis and will only be kept by them for as long as it is reasonably needed for the intended purpose of the services they are providing, after which the data in their possession will be securely destroyed.

At no time and under no circumstances, would your information be sold to any third party for any reason. The data contained in your file will only be kept for as long as it is reasonably needed, and it will only be used for the purpose stated in your file. Once the purpose has been achieved, your file will be deleted unless you require further services, or unless we are required to maintain a copy under applicable law.

You may choose to withhold some or all personal information at any time. However, please understand that your decision may prevent us from providing you with services and information that you request.

Protection

Your information will be stored on a confidential basis at the Teva Support Solutions[®] Patient Support Program offices and/or secure locations both inside and outside of Canada, including within the European Union, Israel, or the USA. It is a condition of receiving services from the Teva Support Solutions[®] Patient Support Program that you expressly consent to the secure storage of your personal information outside Canada. It is protected by various physical, technical and administrative security measures such as magnetic locks, data encryption and a system of individual usernames and passwords for every member of the staff.

Contact on behalf of another person

The Teva Support Solutions[®] Patient Support Program must deal directly and exclusively with you; therefore, it is not possible for others to contact the Teva Support Solutions[®] Patient Support Program on your behalf. If you wish for a family member or a friend or anybody else who is affected by RA to receive services from us, please give him/her our phone number.

Keeping your information accurate

We are committed to keeping your personal information accurate as long as we need it for the purposes previously described. You play an important role in helping us achieve this goal. You may update your information by contacting us either by phone or by email. Your prompt notification of any contact information changes will assist us in providing you the requested services.

Changes to the privacy policy

The Teva Support Solutions[®] Patient Support Program reserves the right to change, modify or amend this policy at any time. However, when a significant change has been made, you will be notified within a reasonable time either by phone, mail or email.

Teva Support Solutions[®] Patient Support Program Privacy Officer

1080 Beaver Hall Hill, Suite 1200
Montreal, Quebec H2Z 1S8
TCI.PrivacyOfficer@tevapharm.com
July 1, 2014

For more information: Please consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00052298.PDF for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

Reference: 1. TRUXIMA[®] Product Monograph. Teva Canada Limited. July 22, 2019.